HC Wainwright Reaffirms Buy Rating for Black Diamond Therapeutics (NASDAQ:BDTX)

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They currently have a $11.00 price target on the stock. HC Wainwright's price target would suggest a potential upside of 236.39% from the company's current price.

A number of other analysts have also issued reports on BDTX. Raymond James began coverage on shares of Black Diamond Therapeutics in a research report on Wednesday, July 31st. They issued an "outperform" rating and a $20.00 price target for the company. Wedbush reaffirmed an "outperform" rating and issued a $16.00 price target on shares of Black Diamond Therapeutics in a research note on Tuesday, October 8th. Finally, Piper Sandler lifted their price objective on Black Diamond Therapeutics from $12.00 to $15.00 and gave the company an "overweight" rating in a research report on Monday, September 23rd.

Black Diamond Therapeutics Trading Up 0.6 %

Black Diamond Therapeutics stock traded up $0.02 during midday trading on Wednesday, hitting $3.27. The stock had a trading volume of 495,137 shares, compared to its average volume of 821,823. Black Diamond Therapeutics has a 12 month low of $1.62 and a 12 month high of $7.66. The business has a fifty day moving average price of $4.27 and a 200 day moving average price of $5.04. The stock has a market cap of $184.77 million, a P/E ratio of -2.47 and a beta of 2.51.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.09. On average, equities analysts anticipate that Black Diamond Therapeutics will post -1.44 EPS for the current fiscal year.

Institutional Investors Weigh In On Black Diamond Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Vontobel Holding Ltd. acquired a new position in Black Diamond Therapeutics during the third quarter worth $68,000. Susquehanna Fundamental Investments LLC acquired a new stake in Black Diamond Therapeutics in the 1st quarter worth approximately $82,000. Foundations Investment Advisors LLC boosted its position in Black Diamond Therapeutics by 17.7% during the second quarter. Foundations Investment Advisors LLC now owns 113,550 shares of the company's stock worth $529,000 after purchasing an additional 17,050 shares during the period. Acadian Asset Management LLC grew its holdings in Black Diamond Therapeutics by 13.8% during the first quarter. Acadian Asset Management LLC now owns 170,510 shares of the company's stock valued at $864,000 after purchasing an additional 20,616 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Black Diamond Therapeutics in the second quarter worth $108,000. Institutional investors and hedge funds own 95.47% of the company's stock.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.